Nascent Biotech Inc
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing Multi… Read more
Nascent Biotech Inc (NBIO) - Total Assets
Latest total assets as of June 2024: $227.39K USD
Based on the latest financial reports, Nascent Biotech Inc (NBIO) holds total assets worth $227.39K USD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nascent Biotech Inc - Total Assets Trend (2014–2024)
This chart illustrates how Nascent Biotech Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Nascent Biotech Inc - Asset Composition Analysis
Current Asset Composition (March 2024)
Nascent Biotech Inc's total assets of $227.39K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 67.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Nascent Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nascent Biotech Inc's current assets represent 100.0% of total assets in 2024, unchanged from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 67.4% of total assets in 2024, down from 99.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Nascent Biotech Inc Competitors by Total Assets
Key competitors of Nascent Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Nascent Biotech Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Nascent Biotech Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Nascent Biotech Inc is currently not profitable relative to its asset base.
Nascent Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.31 | 0.06 | 0.01 |
| Quick Ratio | 0.31 | 0.06 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-514.54K | $ -1.16 Million | $ -801.15K |
Nascent Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Nascent Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 482.01 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | 116.5% |
| Total Assets | $552.12K |
| Market Capitalization | $51.66K USD |
Valuation Analysis
Below Book Valuation: The market values Nascent Biotech Inc's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Nascent Biotech Inc's assets grew by 116.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Nascent Biotech Inc (2014–2024)
The table below shows the annual total assets of Nascent Biotech Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-03-31 | $552.12K | +116.52% |
| 2023-03-31 | $255.00K | +141.91% |
| 2022-03-31 | $105.41K | -85.97% |
| 2021-03-31 | $751.43K | +23250.99% |
| 2020-03-31 | $3.22K | -97.55% |
| 2019-03-31 | $131.47K | +12.37% |
| 2018-03-31 | $116.99K | -87.00% |
| 2017-03-31 | $899.76K | -35.79% |
| 2016-03-31 | $1.40 Million | +49.46% |
| 2015-03-31 | $937.60K | +715.26% |
| 2014-03-31 | $115.01K | -- |